Revenue segments as reported by the company.

Premium and service revenues

Premium tax

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Depreciation

Amortization of acquired intangible assets

Premium tax expense

Health insurer fee expense

Impairment

Legal settlement

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Centene

Centene Corp. operates as a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Managed Care and Specialty Services. The Medicaid Managed Care segment provides health plan coverage to individuals through government subsidized programs through Medicaid. The Specialty Services segment offers healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company was founded in 1984 and is headquartered in St. Louis, MO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Centene exceeds earnings guidance, eyes growth in Marketplace products

Centene's Q4 2022 earnings call highlighted robust financial performance, successful execution of value-creation plans, and a focus on operational efficiency. While challenges in Medicare Advantage margins are anticipated, opportunities in the Marketplace business and cost-cutting initiatives offer avenues for growth. Strategic initiatives to address demographic shifts and enhance care relationships position Centene for future success.

Centene reports strong Q1 earnings, focuses on growth opportunities

Centene's Q1 performance reflects strength in financial results and a strategic outlook for future growth.
Despite challenges in Medicare profitability and Medicaid redeterminations, Centene remains focused on maximizing membership and maintaining high margins.
Opportunities in enhancing relationships, investing in infrastructure, and updating margin assumptions position Centene for long-term success.

Centene reports strong Q2 earnings, raises 2023 outlook amidst challenges

Centene's Q2 earnings call showcased robust financial performance, operational efficiencies, and strategic wins in Medicaid and Marketplace segments. While facing challenges in cost trends and Star ratings strategy, the company is well-positioned for growth through revenue expansion and value-creation initiatives. Opportunities for engagement with key stakeholders and successful outreach efforts present avenues for continued success.

Centene exceeds Q3 earnings expectations, eyes growth opportunities in 2024

Centene's Q3 2023 earnings call highlighted strong financial performance, progress in Medicaid redeterminations, and operational advancements. The company anticipates continued growth in adjusted EPS for 2023 and 2024, with a focus on margin expansion and operational efficiencies. Challenges include managing membership declines and addressing questions on business plans and cost implications.

Centene exceeds 2023 expectations, poised for growth in 2024

Centene's 2023 performance was strong, exceeding expectations and positioning the company for continued growth. Key initiatives in Medicaid, Medicare Advantage, and Marketplace are driving revenue growth and operational efficiency. Challenges in managing utilization trends and achieving target margins require ongoing attention.

Centene surpasses Q1 earnings expectations, eyes growth in Medicaid and Marketplace

Centene's Q1 performance exceeded expectations, showcasing strength in Medicaid and Marketplace segments.
While facing challenges in contract protests and operational clarity, the company's strategic focus on Medicare Advantage and growth opportunities remain key strengths.
With a robust financial outlook and ongoing initiatives for optimization, Centene is well-positioned for continued success in the healthcare market.
Investors can be optimistic about Centene's growth trajectory, supported by strong operational performance and strategic initiatives.

Centene reports robust Q2 earnings, eyes Medicaid rebound and Medicare growth

Centene's Q2 2024 earnings call highlighted strong performance, Medicaid challenges, and growth opportunities in Medicaid and Medicare markets. Leadership transitions and focus on program innovation are key areas of development for the company.

Centene surpasses Q3 earnings expectations, eyes growth amid challenges

Centene's Q3 performance exceeded expectations, driven by improvements in Medicaid and strong Medicare and Marketplace segments.
Despite challenges in Medicaid and competitive pressures, Centene remains confident in its future growth and operational enhancements.
The company's strategic focus on AI, margin expansion, and quality improvement positions it well for continued success and profitability.
Analyst inquiries and company responses highlighted key areas of focus and potential areas for improvement and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, international operations, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene (CNC) collaborates with CHDI to establish a new community center in Texas, reflecting efforts to expand its Managed Care business across the state.

Centene (CNC) Invests Nearly $8M to Build Texas Community Center

Centene (CNC) completes Magellan Rx divestment within the scheduled time.

Centene (CNC) Concludes Magellan Rx Divestment to Prime

ST. LOUIS , Dec. 5, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that it will host an investor day, including a question-and-answer session, on Friday, December 16, 2022. Sarah London, Chief Executive Officer, and other members of the Centene management team, will host the event, which will also be webcast live from the New York Stock Exchange.

CENTENE CORPORATION TO HOST INVESTOR DAY ON DECEMBER 16, 2022

ST. LOUIS , Dec. 5, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has successfully completed the previously announced divestiture of Magellan Rx to Prime Therapeutics LLC (Prime). "We are pleased to continue delivering on our value creation plan with the closing of this transaction, positioning us to remain focused on our core business and strategic priorities on behalf of shareholders," said Sarah London, Chief Executive Officer of Centene.

CENTENE COMPLETES DIVESTITURE OF MAGELLAN RX

Centene and its Texas-based Superior HealthPlan are working with Community Health Development, Inc. on this project State-of-the-art community center will provide access to primary care, behavioral health, youth resources among other services ST. LOUIS , Dec. 5, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today the Centene Charitable Foundation and its Texas health plan, Superior HealthPlan (Superior), have invested $7.9 million in a new, state-of-the-art multipurpose community center in Uvalde, Texas.

CENTENE CORPORATION INVESTS $7.9 MILLION IN UVALDE COMMUNITY CENTER

Divesting operations like PANTHERx, Magellan Specialty Health and others are going to enable Centene (CNC) to intensify its focus on its core Managed Care business.

Why You Should Retain Centene (CNC) in Your Portfolio Now

Elevance Health Inc

T-Mobile US

Visa

Viking Global Investors LP, the firm founded by Andreas Halvorsen (Trades, Portfolio), disclosed in a regulatory filing that its top five trades during the third quarter included the closure of its position in Centene Corp. ( CNC , Financial) and American International Group Inc. ( AIG , Financial), a reduction to its holding of T-Mobile US Inc. ( TMUS , Financial) and boosts to its investments in Visa Inc. ( V , Financial) and Elevance Health Inc. ( ELV , Financial).

Andreas Halvorsen's Top 5 Trades of the 3rd Quarter

Centene (CNC) reported earnings 30 days ago. What's next for the stock?

Why Is Centene (CNC) Down 1.4% Since Last Earnings Report?

Health Net Assisting Members in Alpine, El Dorado, Inyo, Los Angeles and Placer Counties During State of Emergency SACRAMENTO, Calif , Nov. 22, 2022 /PRNewswire/ -- In response to Gov. Gavin Newsom's declared state of emergencies in Alpine, El Dorado, Inyo, Los Angeles and Placer counties, Health Net is providing special assistance to assist members affected by the wildfires and flash flooding.

Health Net Providing Special Assistance to Members Affected by Wildfires, Flash Flooding

Centene (CNC) strikes a deal with Evolent to divest Magellan Specialty Health, a Magellan Health arm, to deepen focus on solidifying its core Managed Care business.

Centene (CNC) to Sell Magellan Arm, To Use Proceeds for Buybacks

Evolent Health

Centene Corp. CNC, +1.79% said late Thursday it has agreed to sell its Magellan Specialty Health benefit-management business to Evolent Health Inc. EVH, +0.21% for $750 million, lauding it as a "milestone" in the health insurer's "value creation program and ongoing portfolio review." Centene bought Magellan Specialty Heath in January as part of its acquisition of Magellan Health, Inc. Upon the deal's closing, Centene and Evolent plan to launch a national multi-year partnership, the company said.

Centene agrees to sell benefit-management unit to Evolent Health for $750 million

Centene to sell Magellan Specialty Health to Evolent Another milestone in Centene's value creation program and ongoing portfolio review Centene and Evolent to create a national strategic partnership Centene expects to receive over $750 million in aggregate proceeds, including potential earnout ST. LOUIS , Nov. 17, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has signed a definitive agreement to sell Magellan Specialty Health to Evolent Health, Inc. (Evolent).

CENTENE SIGNS DEFINITIVE AGREEMENT TO DIVEST MAGELLAN SPECIALTY HEALTH

Accelerates Evolent Health's Value-Based Specialty Care Market Leadership Transaction Anticipated to be Immediately Accretive to Adjusted EBITDA Margins and Cash Flow Highly Complementary Business Expected to Add $85 Million of High-Visibility Adjusted EBITDA by 2024; Maintains Strong Balance Sheet Diversifies Evolent's Revenue Base and Increases Cross-Sell Opportunity from $16 Billion to $50 Billion Expands Centene Customer Relationship with New NIA Contract Expansions and is Expected to Accelerate Pace of Remaining Evolent Cross-Sell Opportunity with Centene WASHINGTON , Nov. 17, 2022 /PRNewswire/ -- Evolent Health, Inc. ("Evolent" or "the Company") (NYSE: EVH) today announced that it has entered into a definitive agreement to acquire NIA (also known as Magellan Specialty Health), the specialty benefit management organization owned by Centene Corporation (NYSE: CNC) that focuses on managing cost and quality in the areas of radiology, musculoskeletal, physical medicine, and genetics. NIA has revenues of approximately $250 million and stand-alone Adjusted EBITDA of approximately $50 million.

EVOLENT HEALTH ANNOUNCES ACQUISITION OF SPECIALTY ASSET NIA AND STRATEGIC PARTNERSHIP WITH CENTENE

ST. LOUIS , Nov. 17, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has successfully completed the previously announced divestiture of its Spanish and Central European Businesses to the French private hospitals group Vivalto Santé. "We are pleased to close this transaction, which represents another key milestone in our value creation plan and enables us to continue focusing on our core business," said Sarah London, Chief Executive Officer of Centene.

CENTENE COMPLETES DIVESTITURE OF ITS SPANISH AND CENTRAL EUROPEAN BUSINESSES

ST. LOUIS , Nov. 16, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today that it has appointed Monte Ford to the Centene Board of Directors, effective November 12 th. Mr. Ford is a leading technologist with more than 20 years of board experience serving Fortune 500 companies across a wide spectrum of industries.

CENTENE APPOINTS MONTE FORD TO BOARD OF DIRECTORS

Baxter

CVS Health

Edwards Lifesciences

Medtronic

Zoetis

Zoetis and Medtronic are among the healthcare stocks with the most room to rise, according to Wall Street analysts' average price targets.

6 Healthcare Stocks With Room to Climb

ST. LOUIS , Nov. 4, 2022 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today it will present at the Credit Suisse 31st Annual Healthcare Conference, to be held Monday, November 7-Friday, November 11, 2022, at the Terreana Resort in California. Centene will present on Tuesday, November 8 th at 9:10 a.m.

CENTENE TO PRESENT AT CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE

This health insurer has market-trouncing potential.

Want Growth at a Reasonable Price? Buy This Powerful Stock and Hold Forever

Ambetter plans offer affordable, accessible coverage for all lifestyles. SACRAMENTO, Calif.

Ahead of Open Enrollment, Ambetter from Health Net plans are Available in Nine Counties Across California

Here is how Centene (CNC) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.

Is Centene (CNC) Outperforming Other Medical Stocks This Year?

Centene's (CNC) third-quarter results reflect solid membership growth within its Medicaid and Medicare businesses. Management currently expects adjusted EPS within $5.65-$5.75 for 2022.

Centene (CNC) Q3 Earnings Top on Medicaid Arm, Revenues Rise Y/Y

Centene Corporation (NYSE:CNC ) Q3 2022 Earnings Conference Call October 25, 2022 8:30 AM ET Company Participants Jennifer Gilligan - SVP, IR Sarah London - CEO & Director Brent Layton - President & COO Andrew Asher - EVP & CFO Conference Call Participants Joshua Raskin - Nephron Research Stephen Baxter - Wells Fargo Securities Justin Lake - Wolfe Research Lance Wilkes - Sanford C. Bernstein & Co. A.J.

Centene Corporation (CNC) Q3 2022 Earnings Call Transcript

Cigna

Express Scripts to manage pharmacy benefits for approximately 20 million Centene members ST. LOUIS , Oct. 25, 2022 /PRNewswire/ -- Express Scripts, the pharmacy benefits management business of Cigna Corporation's (NYSE: CI) Evernorth, announced a new strategic collaboration with Centene (NYSE: CNC) to make prescription medications more accessible and affordable for customers.

Express Scripts Announces Strategic Partnership with Centene to Unlock Greater Prescription Drug Savings

Centene (CNC) delivered earnings and revenue surprises of 6.56% and 1.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Centene (CNC) Tops Q3 Earnings and Revenue Estimates

Managed care company Centene Corp. CNC, +2.65% posted better-than-expected profit and revenue for the third quarter, boosted by a strong performance by Medicaid and Medicare. Centene had net income of $738 million, or $1.27 a share, in the quarter, up from $584 million, or 99 cents a share, in the year-earlier period.

News for Centene Stock (CNC)